Craft

Praxis Precision Medicines

Stock Price

$71

2024-10-29

Market Capitalization

$1.3 B

2024-10-29

Revenue

$8.6 M

FY, 2024

Praxis Precision Medicines Summary

Company Summary

Overview
Praxis Precision Medicines is a company that develops therapies intended for patients and families affected by complex and debilitating brain disorders. Its therapy targets genes that control the imbalance in neuronal signaling that underlies CNS disorders, enabling patients to get treatment for psychiatric disorders, movement disorders, and rare pediatric epilepsies.
Type
Public
Status
Active
Founded
2015
HQ
Cambridge, MA, US | view all locations
Website
https://praxismedicines.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Marcio Souza

    Marcio Souza, President and Chief Executive Officer

  • Steven Petrou

    Steven Petrou, Co-Founder & Chief Scientific Officer

    • Tim Kelly

      Tim Kelly, Chief Financial Officer

    • Karl Hansen

      Karl Hansen, Chief Technical Operations Officer

    Operating MetricsView all

    Discovery Stage Products

    1

    Q2, 2020

    Pre-Clinical Phase Products

    1

    Q2, 2020

    Phase I Trials Products

    1

    Q2, 2020

    LocationsView all

    1 location detected

    • Cambridge, MA HQ

      United States

      1 Broadway

    Praxis Precision Medicines Financials

    Summary Financials

    Cash (Q1, 2026)
    $536.3M
    EBIT (Q1, 2026)
    ($105.9M)
    Enterprise value
    $726.4M

    Footer menu